Board of Directors

Board of Directors

Dr. Lance Willsey
Chairman of the Board
Dr. Lance Willsey was appointed Chairman of the Board on September 30, 2024. He was appointed member of the Board of Directors in December 2023. Dr. Lance Willsey, M.S., M.D. is a urologist who has an aggregate of 36 years of private and public board experience focused in the area of cancer diagnostics and therapeutics. He completed his surgical and urology training at the Massachusetts General Hospital and additional postgraduate training in the Steele Lab Harvard University and the Dana Farber Cancer Institute. Lance is a founding Partner of Healthcare fund DCF Capital. He also actively participated in boards as a Director of Exact Sciences from 1999 to 2009 and of Exelixis from 1997 to 2023. Lance helped guide the two companies through their IPO process as well as subsequent financings. He also has extensive experience in corporate governance having served on audit, compensation, finance and scientific advisory committees.
Independent Director
Pierre Beysson

Pierre Beysson was appointed as a member of the Board of Directors in September 2002. Pierre Beysson was then the Chief Financial Officer of Compagnie des Wagons-Lits ("CWL"), the on-board train service division of Accor, a French multinational Hotel and Business Services Group. In this capacity, he sat on a number of boards of companies related to the Accor Group. Before his assignment at CWL, Pierre Beysson held a number of senior financial positions with Nixdorf Computers, Trane (Air Conditioning), AM International (Office Equipment) and FMC (Petroleum Equipment). Pierre Beysson was trained as a CPA, has auditing experience and holds an MBA from Harvard Business School.

 

Independent Director
Marie Meynadier
Marie Meynadier was appointed as a member of the Board of Directors in June 2020. Marie Meynadier currently serves on the Boards of Directors of several medical technology companies in Europe and North America. From 1999 through 2019, she served at EOS Imaging as its CEO. Prior to EOS Imaging, Ms. Meynadier served as CEO at Biospace Lab, a preclinical imaging company she developed and turned to profitability. Ms. Meynadier received a degree in electrical engineering from Sup Télécom, Paris, and her Ph.D. in physics from Ecole Normale Supérieure Ulm, Paris.
Independent Director
Ryan Rhodes
Chief Executive Officer
Ryan Rhodes was appointed as a member of the Board of Directors in August 2023. Ryan was appointed Chief Executive Officer of Company on May 1, 2023, to lead, strengthen and accelerate the Company’s corporate strategy and development. Mr. Rhodes is a passionate executive with over 30 years of leadership experience in market development in the medical device industry, including 20 years dedicated to medical robotics.  Prior to joining EDAP, Ryan served as the CEO of Restoration Robotics, the global leader in robotic aesthetic medicine where he led the company to a successful merger with Venus Concept Inc. in 2019.  Prior to Restoration Robotics, Ryan spent over 13 years at Intuitive Surgical, the global leader in medical robotics where he was a key architect of the company’s multi-procedure market focus and development efforts, including the successful launch of the global Urology franchise.  Prior to Intuitive Surgical, he spent over 11 years in various management positions in sales, marketing, professional education, and market development at Ethicon Inc., a Johnson & Johnson Company.  Ryan holds a B.A in Public Administration from San Diego State University.
Fran Schulz

Ms. Schulz was appointed as a member of the Board of Directors in June 2024. Ms. Schulz is a seasoned executive with over 35 years of experience with EY who has spent her career working with large public and emerging private companies throughout the life sciences industry. She has deep experience guiding companies to execute a broad range of corporate deals including collaboration agreements, corporate spin-offs, reorganizations, and mergers and acquisitions, with personal involvement in over 100 total equity and debt transactions, raising over $15 billion in aggregate. Ms. Schulz also has significant experience with the U.S. Securities and Exchange Commission (SEC) and International Financial Reporting Standards (IFRS). As one of the founding members and senior partners in EY’s Life Sciences Practice, Ms. Schulz directly contributed to the growth of EY into a $45B firm recognized on the Fortune 100 Best Companies to Work For® list 22 years in a row. She is also qualified to serve as a financial expert under SEC, NYSE and NASDAQ rules.

Independent Director